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Abstract The DNA sequence encoding a novel human thio-
redoxin reductase has been determined. The protein is predicted
to have 524 amino acids including a conserved -Cys-Val-Asn-
Val-Gly-Cys catalytic site and a selenocysteine containing C-
terminal -Gly-Cys-SeCys-Gly. The predicted molecular mass is
56.5. The newly identified TR sequence exhibits 54% identity to
a previously reported human thioredoxin reductase and 37%
identity to human glutathione reductase. Transient transfection
of human embryonal kidney cells results in a 5-fold increase in
thioredoxin reductase activity but no increase in glutathione
reductase activity.
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1. Introduction
Thioredoxin reductase (TR) is a dimeric NADPH-depend-
ent FAD containing enzyme that catalyzes the reduction of
the active site disul¢de of thioredoxin and other substrates [1].
TR is a member of a larger family of pyridine nucleotide-
disul¢de oxidoreductases, which includes lipoamide dehydro-
genase, trypanothione reductase and glutathione reductase [2].
Thioredoxin is a low molecular weight (10^12 kDa) redox
protein found in both prokaryotic and eukaryotic cells [1].
The cysteine residues at the conserved -Cys-Gly-Pro-Cys-Lys
active site of thioredoxin undergo reversible oxidation-reduc-
tion catalyzed by TR [3]. Thioredoxin is a reducing cofactor
for ribonucleotide reductase, which catalyzes the ¢rst unique
step in DNA synthesis [4]. Through thiol-disul¢de exchange,
TR exerts redox control over transcription factors NF-UB [5]
and glucocorticoid receptor [6], and indirectly through a nu-
clear redox factor Ref-1/HAPE, AP-1 (Fos/Jun heterodimer)
[7] to modulate their binding to DNA. A number of human
primary cancers such as lung, colon, cervical and liver cancers
have been shown to over-express thioredoxin [8^11]. Trans-
fection of cancer cells with thioredoxin can increase tumor
growth and inhibits anti-cancer drug-induced apoptosis [12].
Redox activity is necessary for this e¡ect as shown by the
potentiation of apoptosis and a dominant-negative inhibition
of tumor growth by transfection with a redox inactive mutant
of thioredoxin ([13] and unpublished observations). Thus, the
thioredoxin redox system plays an important role in cell
growth and death.
Bacterial TR is highly speci¢c for thioredoxin as a substrate
[1]. In contrast, mammalian TR catalyzes the reduction of a
variety of substrates including low molecular weight disul¢des
such as dithionitrobenzoate (DTNB) [3] and lipoic acid [14],
and non-disul¢des including selenite [15], alloxan [16] and
lipid hydroperoxides [17]. Rat liver TR has also been reported
to reduce dehydroascorbic acid to ascorbic acid and may be
required for the maintenance of liver ascorbate content [18].
Mammalian TRs have been puri¢ed and have estimated
subunit molecular weights of 58 kDa for the bovine enzyme
[3], 58 kDa for the rat liver enzyme [3], and 65 kDa for the
human placental enzyme [19]. The sequence of a human TR
cDNA from a placental library predicts a protein with a mass
of 54 kDa and high similarity (44% identity) to glutathione
reductases, with a conserved -Cys-Val-Asn-Val-Gly-Cys- re-
dox active site [20]. Subsequent work identi¢ed two human
proteins with TR activity, one with a subunit molecular
weight of 55 kDa from Jurkat T cells [21] and the other 57
kDa from lung adenocarcinoma cells [22]. The carboxy-termi-
nal peptide sequences were identical to that predicted for hu-
man placental TR but contained a terminal selenocysteine
(SeCys) residue, giving -Gly-Cys-SeCy496-Gly497 instead of
the predicted terminal Gly-Cys495. This ¢nding indicated
that the human TR mRNA TGA encodes SeCys rather
than acting as a stop codon [23]. Previous studies have shown
that speci¢c stem loop structures, termed SECIS (SeCys in-
corporation sequence) elements present in the 3P untranslated
regions of mRNAs are required to signal the cell to insert a
SeCys at a TGA codon rather than terminating protein syn-
thesis [24,25]. A putative SECIS element was identi¢ed be-
tween base pairs 2181 and 2226 of human TR mRNA [26].
The carboxy-terminal SeCys is required for the thioredoxin
reductase activity of the enzyme. Expression in baculovirus
of recombinant human TR lacking SeCys, either as a trun-
cated protein or with Cys instead of SeCys, results in abolition
of enzyme activity with thioredoxin as a substrate but the
enzyme still retains some DTNB reducing activity [26]. Enzy-
matic cleavage of the carboxy-terminus SeCys of bovine TR
with carboxypeptidase also results in a loss of enzyme activity
[27].
Since the cloning of human placental TR [20], a rat neuro-
blastoma derived TR cDNA has been cloned [27] and much of
the bovine liver TR protein sequenced, both showing high
homology to the human placental TR [27]. Here, we report
the cloning of a novel human TR with high homology to the
previously cloned human TR. A putative SECIS element ex-
hibiting all the conserved features required for function is
present in the 3P untranslated region of the sequence. We
also report functional expression of this novel TR in human
cells and analysis of expression in a number of human tissues
and cancer cell lines.
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2. Materials and methods
2.1. Cloning
A Vgt11 human placenta 5P stretch cDNA library (Clontech, Palo
Alto, CA) was screened using the BglII-SmaI fragment of human TR
(bp 171^723) which contains the coding sequence for the -Cys-Val-
Asn-Val-Gly-Cys- active site [20] as a probe. The BglII-SmaI fragment
was labeled with [K-32P]dCTP using RadPrime (Gibco BRL, Gaithers-
burg, MD) according to the manufacturer’s instructions. Approxi-
mately 105 plaques were hybridized in 0.5 M sodium phosphate, pH
7.2, 10 mM EDTA, 7% sodium dodecyl sulfate and 1% bovine serum
albumin at 50‡C for 72 h. The ¢lters were washed with 2USSC (0.3 M
sodium chloride, 0.33 M sodium citrate), 0.05% sodium dodecyl sul-
fate at 50‡C. The cDNA inserts of six positive plaques were screened
using the polymerase chain reaction (PCR) with the cDNA insert
screening amplimers for Vgt11 (Clontech, Palo Alto, CA). 5P insert
screening amplimer: 5P-GAC TCC TGG AGC CCG-3P, 3P insert
screening amplimer: 3P-CGC GGC CAG CGA TGG-5P. PCR was
performed with 25 cycles of 94‡C for 1 min, 60‡C for 1 min, 27‡C
for 1 min, and 1 cycle of 72‡C for 10 min. The PCR fragments were
separated on a 1% agarose gel and gel puri¢ed using QIAquick Gel
Extraction kit (Qiagen, Valencia, CA). The puri¢ed fragments were
digested with EcoRI and cloned into pBluescript, digested with EcoRI
(Stratagene, La Jolla, CA) and the cDNA inserts sequenced on an
Applied Biosystems 377 DNA £uorescent automated DNA sequenc-
ing system. cDNA clone number 5 which was determined to be 71%
identical to TR was used to rescreen the human placenta cDNA
library obtaining eight positive plaques. One cDNA (clone 30) was
found upon sequencing to be similar but not identical to TR with a
long open reading frame and missing both the 5P and 3P ends. Re-
screening the placenta cDNA library with [K-32P]dCTP-labeled cDNA
30 as a probe yielded no additional cDNA sequences. Next, a human
heart cDNA library in lambda ZAP II (Stratagene, La Jolla, CA) was
screened with cDNA 30 giving four positives plaques. The cDNA
inserts were excised using the Exassist/SOLR in vivo excision protocol
according to the manufacturer’s instructions. Two clones, H15 and
H19, contained additional cDNA sequence, but not the complete
coding region or the polyA tail.
To obtain the 5P and 3P ends of cDNA 30, a human fetal heart
cDNA library (Gibco BRL, Gaithersburg, MD) with average insert
size of 2.2 kb was screened. cDNA clones were isolated using the
Gene Trapper cDNA Positive Selection System (Gibco BRL, Gai-
thersburg, MD). Double stranded DNA was prepared from the hu-
man fetal heart cDNA library according to the manufacturer’s in-
structions. Oligonucleotide F167-2 (GCC ACC GTG TCC AGC
TTC AG) was polyacrylamide gel puri¢ed (Bio-synthesis, Lewisville,
TX), phenol:chloroform:isoamyl alcohol (25:24:1) extracted, precipi-
tated with 7.5 M ammonium acetate, resuspended in 10 mM Tris-HCl
bu¡er, pH 7.5, 1 mM EDTA and biotinylated using biotin-14-dCTP
according to the manufacturer’s instructions. Biotinylation reaction
products were analyzed on a 16% polyacrylamide gel. The library
DNA was made single stranded using Gene II and Exo III according
to the manufacturer’s instructions. The products were analyzed on a
0.8% agarose gel in 40 mM Tris-acetate, pH 7.2, 10 mM EDTA.
Biotinylated F167-2 was hybridized with the single stranded DNA
and this mixture was incubated with streptavidin paramagnetic beads.
The captured cDNA was repaired to double stranded using non-bio-
tinylated oligonucleotide F167-1 (GTG CCG CAT GAC TGG AGG
AAG). The repaired cDNA was ethanol precipitated and Electromax
DH10B cells (Gibco BRL, Gaithersburg, MD) were transformed with
2 Wl of the cDNA by electroporation using the Cell-Porator system
(Gibco BRL, Gaithersburg, MD). The conditions for electroporation
were: 23 Wl of cells, 0.15 gap chamber at settings of voltage: 400;
capacitance 330 WF; impedance: low ohms; charge rate: fast; and
resistance on voltage booster: 4000 6. Electroporated cells were
plated on LB (Luria-Bertani medium) containing 100 Wg/ml ampicillin
and incubated overnight at 37‡C. Positive cDNA clones were identi-
¢ed by colony PCR. Twenty-four colonies were screened. A master
mix containing 22.5 Wl of PCR Supermix (Gibco BRL, Gaithersburg,
MD), 0.5 Wg oligonucleotide F167-1, 0.5 Wg oligonucleotide D905-4
(ATG TGA TCG GCT GAC AGC AG) and distilled water to 25 Wl
per reaction was made. One half of each colony was added to 25 Wl of
the master mix and ampli¢ed by PCR using the following program:
1 cycle, 94‡C 1 min; 30 cycles of: 94‡C, 52 s, 55‡C, 1 min 9 s, 72‡C,
1 min 17 s. Ten microliters of each reaction were analyzed on a 1%
agarose gel. One cDNA product out of the 24 had the predicted size
of 190 bp. The other half of this colony was grown at 37‡C in LB with
100 Wg/ml ampicillin overnight. DNA was prepared using Quantum
Prep (Bio-Ras, Hercules, CA) and the construct digested with NotI
and SalI. The digest was analyzed on a 1% agarose gel in 40 mM Tris-
acetate, pH 7.2, 10 mM EDTA and the cDNA insert was determined
to be approximately 2.2 kb. The insert was sequenced and found to
contain the complete coding sequence and additional sequences at the
5P and 3P ends of the cDNA 30. Sequence information was compiled
and analyzed using the algorithms available through GCG (Genetics
Computer Group Inc., Madison, WI). DNA and protein data bases
were searched using the computer programs FASTA and BLASTP
performed at the NCBI (National center for Biotechnology Informa-
tion) using the BLAST network service (GCG). Gapped sequence
alignments and identity/similarity comparisons were made using the
PILEUP computer program (GCG).
2.2. Transfection
Transformed primary human 293 embryonal kidney cells were
grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM) with 10%
fetal bovine serum (FBS) and 100 nM sodium selenite for 4 days prior
to transfection. Cells were seeded at approximately 50% con£uence in
33 mm dishes and 24 h later 1 ml DMEM with 2% FBS, 100 nM
sodium selenite, 120 Wl of LipoTAXI transfection reagent (Stratagene,
La Jolla, CA) and 40 Wg cDNA of either TR-K/pCMV-Sport2 or TR-
L/pCMX, together with 20 Wg Xenopus SeCys-tRNA/pGEM3 [28]
were added to each dish. The cells were incubated for 24 h at 37‡C,
the medium removed and replaced with DMEM with 10% FBS and
100 nM sodium selenite. The cells were incubated at 37‡C for 24 h
before assaying for TR and glutathione reductase activities.
2.3. Subcellular fractionation
MCF-7 human breast cancer cells were grown to 80% con£uence in
roller culture bottles. The cells were washed twice with phosphate
bu¡ered saline and 5U108 cells were scraped free and homogenized
using 60 strokes of a tightly ¢tting Dounce homogenizer in 30 ml
homogenization bu¡er consisting of 10 mM Tris bu¡er, pH 7.4,
10 mM NaCl, 3 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM
phenylmethylsulfonyl £uoride, 10 Wg/ml leupeptin, and 10 Wg/ml apro-
tinin at 4‡C. The homogenate was centrifuged at 650Ug for 20 min
and the resulting pellet re-homogenized in 2.4 M sucrose, 3.3 mM
CaCl2 and centrifuged at 650Ug for 30 min. The upper third layer
was diluted 1:10 with 3.3 mM CaCl2, layered over 1 M sucrose and
centrifuged at 900Ug for 30 min to give a pellet which was resus-
pended, washed by twice by centrifugation in homogenization bu¡er
and ¢nally suspended in 15 ml homogenization bu¡er as the nuclear
fraction. The supernatant resulting from the ¢rst homogenization step
was centrifuged at 110 000Ug for 60 min to give a pellet which was
resuspended and washed by centrifugation, twice, in homogenization
bu¡er and ¢nally suspended in 15 ml homogenization bu¡er as the
microsomal fraction. The post-microsomal supernatant was again cen-
trifuged at 110 00Ug to give the cytosol fraction. All fractions were
stored frozen at 380‡C
2.4. Enzyme assays
Cells were lysed by homogenizing in 50 mM Tris bu¡er, pH 7.3,
1 mM EDTA. TR activity [29] and glutathione reductase activity [30]
in the total cell lysate were measured spectrophotometrically at 339
nm by the initial rate of oxidation of NADPH as previously de-
scribed.
2.5. Northern blotting
To determine the distribution of TR-L cDNA in human tissues a
full length probe was labeled with [K-32P]dCTP and used to hybridize
with Human Multiple Tissue Northern (MTN) Blot and Human Mul-
tiple Tissue Northern Blot IV (Clontech, Palo Alto, CA). The hybrid-
ization bu¡er was 0.5 M sodium phosphate, pH 7.2, 10 mM EDTA,
7% sodium dodecyl sulfate and 1% bovine serum albumin and hybrid-
ization was performed at 65‡C for 18 h. The blots were washed with
0.04 M sodium phosphate pH 7.2, 1% sodium dodecyl sulfate, 1 mM
EDTA at 65‡C for 20 min. Blots were quantitated by densitometry
using an Eagle Eye II (Stratagene, La Jolla, CA).
2.6. Western blotting
The distribution of TR-L protein was determined in a panel of
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human tumor cell lines. The cell lines were obtained from the Amer-
ican Tissue Type Collection (Rockville, MD) or the National Cancer
Institute (Bethesda, MD). The cells were grown and homogenized as
previously described. Rabbit polyclonal antisera were raised against
two unique internal peptide sequences of the TR-L (30-1, IKASFV-
DEHTVCGVAKG, amino acids 157^153; and 30-2, ARHGQEHVE-
VYHAHYK, amino acids 417^432) coupled to the multiple antigen
peptide (MAP) conjugation system (Bio-Synthesis Inc., Lewisville,
TX). Rabbits are injected at several sites with 1 mg of the AP-peptide
in 0.5 ml TiterMax Gold adjuvant (CytRx Corp., Norcross, GA) and
antisera collected 1 month later. Western blotting was conducted as
previously described [9] with 40 Wg total cell lysate per lane using
antiserum 30-2, which showed no cross-reactivity with peptide 30-1
or with puri¢ed human placental TR, at a dilution of 1:4000. Detec-
tion was by the Renaissance chemiluminescence system (NEN Life
Science Products, Boston, MA).
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Fig. 1. Nucleotide sequence and deduced amino acid sequence of human TR-L. The box shows the conserved active site. The penultimate pre-
dicted amino acid residue is selenocysteine designated C*.
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3. Results
3.1. Cloning and sequence analysis
Fig. 1 shows the consensus sequence for the new human
TR, designated here TR-L to distinguish it from the reported
human TR designated TR-K. The predicted amino acid se-
quence of TR-L has two potential ATG start codons in close
proximity. The longest open reading frame gives a protein
with 524 amino acids and a molecular mass 56 540. TR-L
has the conserved -Cys-Val-Asn-Val-Gly-Cys active site of
TR-K and a selenocysteine (SeCys) residue in the carboxy-
terminal -Gly-Cys-SeCys-Gly. The predicted amino acid se-
quence of TR-L showed highest identity to a rat TR (79%)
(GenBank accession number AF0722865) and to human TR-
K (54%) [20] (Fig. 2). TR-L exhibits 37% identity to human
glutathione reductase. TR-L exhibits an N-terminal extension
with a high content of positively charged amino acids com-
pared to TR-K. The motif search program Prosite (GCG) did
not identify a nuclear or mitochondrial localization sequence
in TR-L.
A sequence search of the 3P untranslated region for the
conserved motifs present in SECIS elements, followed by
computer and manual folding of the candidate regions, re-
vealed a single region satisfying all of the consensus SECIS
sequence and structure requirements [31^33]. Comparison of
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Fig. 3. Predicted TR-K and TR-L SECIS structures. Conserved nu-
cleotides present in all SECIS elements are shown in bold.
Fig. 2. Alignment of the predicted amino acid sequence of TR-L (H-TRX-L) with human TR-K (H-TRX-K) and human glutathione reductase
(H-GSHR). Identical amino acid residues are shown in black boxes. The penultimate SeCys amino acid of both TR-L and TR-K is designated
by C*.
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the putative TR-L element with that of TR-K reveals little
primary sequence conservation aside from the invariant nu-
cleotides shown in bold, but the predicted structures are quite
similar, though not identical (Fig. 3). The relative positions of
the two SECIS elements in the 3P untranslated regions are also
quite similar: 253 and 272 nucleotides downstream of the
UGA codon in TR-K and TR-L, respectively.
3.2. Northern hybridization
The relative expression patterns of TR-L mRNA and TR-K
mRNA in human tissues were compared by Northern analysis
(Fig. 4). The highest levels of TR-L mRNA were found in
prostate, testis, liver, uterus and small intestine, with inter-
mediate levels in brain, skeletal muscle, heart and spleen,
and low levels in placenta, kidney, pancreas, thymus and pe-
ripheral blood leukocytes. This pattern of expression is dis-
tinct from that exhibited by TR-K.
3.3. Western blotting analysis
TR-L protein expression patterns were assessed in MCF-7
cell subcellular fractions by Western analysis with a polyclo-
nal antiserum made against a synthetic TR-L peptide (Fig. 5).
A predominant band of approximately 54 kDa was found in
the cytosol and associated with the microsomal fraction. A
fainter band at approximately 58 kDa was also seen. In con-
trast, TR-K protein was predominantly associated with the
microsomal fraction. Neither TR-K or TR-L are integral
membrane proteins and their association with the microsomal
fraction could be reversed by washing in 2 M NaCl (results
not shown). Relative protein levels for TR-L were assessed in
a panel of human tumor cell lines (Fig. 6). A protein band of
54 kDa was found at high levels in HT-29 colon cancer,
MCF-7 breast cancer and Jurkat T cell leukemia lines. Weak-
er 56 kDa and 58 kDa protein bands were also apparent in
some of the cell lines.
3.4. Expression of thioredoxin reductase activity
Transfection of human 293 kidney cells with TR-L cDNA
resulted in a 5.5-fold increase in thioredoxin reductase activity
of the cells compared to a 4.5-fold increase using TR-K cDNA
(Fig. 7). Interestingly the background activity of reduction of
insulin in the absence of thioredoxin was also increased about
4-fold by TR-L cDNA, but not by TR-K cDNA, suggesting
that TR-L can directly reduce proteins such as insulin. The
inclusion of 100 nM selenium in the growth medium increased
the expression of TR activity from TR-L (results not shown).
The TR-L cDNA transfected cells showed no increase in glu-
tathione reductase activity with a value ( þ S.E.M., n = 4) of
6.7 þ 1.5 nmol/min/mg protein in the TR-L transfected cells,
compared to 8.5 þ 0.5 nmol/min/mg in mock-transfected cells
and 8.1 þ 0.6 nmol/min/mg in the Xenopus SeCys-tRNA trans-
fected cells (P6 0.05 in both cases).
4. Discussion
The possibility of multiple forms of human TR has been
raised by the identi¢cation of two distinct proteins of 55 and
57 kDa exhibiting TR activity and penultimate carboxy-ter-
minal SeCys in human tumor cells [21,22]. The 57 kDa form
of TR from HeLa and human lung adenocarcinoma cells has
been reported to further consist of two forms, a heparin bind-
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Fig. 5. TR-K and TR-L levels in di¡erent subcellular fractions of
MCF-7 human breast cancer cells measured by Western blotting.
The arrow shows the size of the protein.
Fig. 4. Northern hybridization analysis of TR-L mRNA in human tissues. Also shown for comparison is TR-K mRNA. The values underneath
are relative levels corrected for expression of histone mRNA (not shown).
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ing and a non-heparin binding form with only the non-hep-
arin binding form showing cross-reactivity with anti-rat liver
polyclonal antibody [34]. This was suggested to be due to a
post-translational modi¢cation of the TR protein although
mammalian TR is not a glycoprotein. Two distinct rat TRs,
exhibiting 82% amino acid sequence identity have been re-
ported ([27] and GenBank accession number AF072865).
We report the identi¢cation and initial characterization of a
novel human TR, di¡ering in molecular mass and exhibiting a
distinct pattern of human tissue expression from that previ-
ously described for TR-K. The predicted mass of TR-L of 56.5
kDa agrees well with the apparent mass of 54 kDa measured
by SDS polyacrylamide gel electrophoresis and Western blot-
ting. TR-L has 54% identity to the previously described TR-K
with the same catalytic site but an N-terminal extension.
We predict TR-L to be a selenoprotein with a carboxy-ter-
minal -Gly-Cys-SeCys-Gly, rather than ending in -Gly-Cys, as
would be predicted by TGA functioning as a stop codon.
Several pieces of evidence support this. First, the predicted
SeCys-containing carboxy-terminus of TR-L is homologous
with that of TR-K, a known SeCys containing protein [22].
Second, the 3P untranslated region contains a consensus SE-
CIS element. Third, co-transfection of 293 cells with Xenopus
SeCys-tRNA cDNA, encoding the tRNA which delivers Se-
Cys to the growing polypeptide [35], markedly increases the
expression of TR activity. Fourth, supplementation of the
growth medium with selenium further increases the expression
of TR activity from TR-L, as reported for TR-K [36].
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